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New tuberculosis drug regimens are creating new priorities for drug susceptibility testing (DST) and surveillance. To 
minimise turnaround time, rapid DST will need to be prioritised, but developers of these assays will need better data 
about the molecular mechanisms of resistance. Eﬀ orts are underway to link mutations with drug resistance and to 
develop strain collections to enable assessment of new diagnostic assays. In resource-limited settings, DST might not 
be appropriate for all patients with tuberculosis. Surveillance data and modelling will help country stakeholders to 
design appropriate DST algorithms and to decide whether to change drug regimens. Finally, development of practical 
DST assays is needed so that, in countries where surveillance and modelling show that DST is advisable, these assays 
can be used to guide clinical decisions for individual patients. If combined judiciously during both development and 
implementation, new tuberculosis regimens and new DST assays have enormous potential to improve patient 
outcomes and reduce the burden of disease.
Introduction
Patient care algorithms can be improved in two main 
ways: by rethinking and reorganising existing methods 
and technologies, and by introducing new technologies. 
In recent decades, national tuberculosis programmes 
have used existing technologies more eﬀ ectively than in 
previous decades, achieving substantial results.1 But 
further improvement is restricted by outdated and 
inadequate methods used to ﬁ ght the epidemic: a vaccine 
with limited eﬀ ectiveness; a drug regimen that is long 
and that places substantial demands on patients and 
health-care systems; and a diagnostic technique (smear 
microscopy) that detects only half of all cases and does 
not assess drug resistance of the infecting Mycobacterium 
tuberculosis strain.2
As eﬀ orts to improve these methods accelerate, 
investigators now have to consider how these various 
approaches will work together within a health system. 
Rapid development of resistance could occur if new drugs 
are added to failing regimens, or if combination regimens 
are used widely in populations that have substantial 
existing resistance to some of the drugs in those 
combinations. In some cases this resistance might leave 
only one eﬀ ective drug in a regimen, increasing the 
chance of developing additional resistance and severely 
limiting the antimicrobial arsenal even further. Therefore, 
new tuberculosis regimens3 cannot be introduced without 
development of drug susceptibility testing (DST) assays 
suited to the new regimens. DST can be used to monitor 
patterns of emerging drug resistance and to direct patients 
towards appropriate therapy, but careful analysis is needed 
to establish the optimum DST strategy for each new drug 
regimen and each diﬀ erent epidemiological context. 
The primary backbone of tuberculosis treatment has 
not changed for decades; thus, susceptibility tests for 
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Key messages
• Advances in new drug regimens and diagnostics for 
tuberculosis, including drug susceptibility testing (DST), 
are exciting; however, strategies should be aligned to 
promote co-introduction for optimum results 
• Tuberculosis treatment should ideally be based on full 
information about drug susceptibility of the infecting 
strain; however, at least in the short term and in 
resource-limited settings, less comprehensive DST might 
be more feasible or advisable in some countries; potential 
gains from DST should be balanced against costs, 
complexity, and predicted loss to follow-up
• DST and drug resistance surveillance are particularly 
important for existing and repurposed drugs, such as 
pyrazinamide and ﬂ uoroquinolones, that are being tested 
in ﬁ rst-line regimens and for which resistance already exists
• DST should be rapid to maximise patient retention and 
ensure prompt treatment with eﬀ ective regimens, thus 
minimising the generation and spread of resistance; a 
rapid DST assay will probably need to detect molecular, 
rather than phenotypic, correlates of resistance
• To improve molecular tests, further research is needed to 
establish the genetic basis for resistance to existing and 
new drugs and to link each mutation with clinical eﬀ ect; 
surveillance is needed to establish the background level of 
resistance
• This information can be used by modellers to assess the 
potential eﬀ ectiveness of diﬀ erent scenarios of drug and 
diagnostic introduction; by product developers to better 
deﬁ ne product speciﬁ cations; and by country 
programmes and providers to better assess whether, and 
how, to adopt new products
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additional drugs have not received much attention.4 But 
regimens with new tuberculosis drugs will change 
priorities for DST and drug resistance surveillance. 
Resistance against drugs in new ﬁ rst-line regimens will 
be particularly important to test for, especially since 
existing tuberculosis drugs are easily available in the 
private sector—in large volumes, and with little or 
no regulation—in many high tuberculosis burden 
countries.5
Through the Tuberculosis Diagnostics Research 
Forum, several partners are working to ensure that the 
necessary DST assays are developed in time for co-
implementation with new tuberculosis drug regimens. 
The aim is to develop a framework for designing DST for 
new regimens. Such DST should meet at least the same 
performance criteria as DST for existing ﬁ rst-line 
therapy. The ultimate goal is to have suﬃ  cient infor-
mation—including prevalence of existing resistance—so 
that all patients with tuberculosis can be conﬁ dent that 
their regimen will be safe and eﬀ ective. 
To reach these goals, translational science is needed to 
provide the basis for molecular diagnostics development. 
Furthermore, surveillance data and modelling are needed 
to design DST protocols and to guide decisions on 
regimen changes. And, in countries where the 
surveillance and modelling show that DST assays are 
necessary, development and use of these assays are 
needed to guide clinical decision making for individual 
patients. In this Series paper, we discuss alignment of 
new tuberculosis regimens and tuberculosis DST, and we 
outline the actions needed for the optimum, coordinated 
introduction of new technologies for tuberculosis 
control.
Tuberculosis regimens: past, present, and future 
First-line tuberculosis treatment has gradually evolved 
from monotherapy with streptomycin, to multidrug 
regimens of up to 24 months or more, and ﬁ nally to the 
so-called short-course regimen now used in most high-
burden countries.6 This regimen is a 6 month course of 
treatment denoted as 2HRZE/4HR: a 2 month intensive 
phase of isoniazid (H), rifampicin (R), pyrazinamide (Z), 
and ethambutol (E) followed by a 4 month continuation 
phase of isoniazid and rifampicin. It has been the global 
standard ﬁ rst-line tuberculosis treatment for decades. 
The duration of the 6 month regimen puts substantial 
demands on health-care systems and patients.7,8 
Meanwhile, second-line tuberculosis treatment, for 
patients with multidrug-resistant (MDR) tuberculosis 
(deﬁ ned by resistance to both isoniazid and rifampicin), 
is based only on observational studies and expert 
opinion.9 These multidrug regimens of 18–24 months 
are toxic, expensive, and of limited eﬀ ectiveness.10 The 
inadequacy of these regimens, which has become 
increasingly evident as more people are diagnosed with 
MDR tuberculosis, has led to eﬀ orts to ﬁ nd and develop 
new tuberculosis drug regimens that would shorten 
ﬁ rst-line treatment, avoid drug–drug interactions with 
antiretroviral therapy, and improve second-line 
treatment.3,11
Two phase 3 trials of shorter duration ﬁ rst-line 
tuberculosis treatment have now completed patient 
enrolment and treatment. The OFLOTUB trial12 
replaced ethambutol with the ﬂ uoroquinolone 
gatiﬂ oxacin in a 4 month regimen, although gatiﬂ oxacin 
has subsequently lost regulatory approval in many 
countries because of adverse events. The REMoxTB 
trial13 replaced either isoniazid or ethambutol with the 
ﬂ uoroquinolone moxiﬂ oxacin (M) in two experimental, 
4 month regimens (2HRZM/2HRM and 2MRZE/2MR). 
Results from REMoxTB are expected in late 2013; if 
positive, regulatory approval will be sought in 2014 and 
a national launch could start as early as 2015. 
Next-generation, ﬁ rst-line regimens are likely to 
include several new drugs.14 Clinically, the most advanced 
regimen15,16 in this category is known as PaMZ, a 
combination of the novel nitroimidazo-oxazine PA-824, 
moxiﬂ oxacin, and pyrazinamide. This regimen has the 
potential not only to shorten the duration of ﬁ rst-line 
treatment, but also to treat a proportion of patients who 
would previously have needed second-line treatment—
ie, patients with MDR tuberculosis.17 
Finally, several tuberculosis drug candidates are in 
clinical development, but their optimised regimens have 
not yet been deﬁ ned. Sutezolid (PNU-100480), an 
analogue of linezolid, is in phase 2a trials. More advanced 
are two new drugs that have been submitted for 
regulatory approval for treatment of MDR tuberculosis 
on the basis of phase 2b data. Bacterial burden was 
reduced more quickly when either bedaquiline (a 
diarylquinoline formerly known as TMC207)18 or 
delamanid (a nitro-dihydro-imidazooxazole formerly 
known as OPC-67683)19 was added, for 6 months, to an 
optimised background regimen for MDR tuberculosis.18,19 
Bedaquiline was granted marketing approval by the US 
Food and Drug Administration on Dec 28, 2012. However, 
the extent to which these drugs can shorten and simplify 
MDR tuberculosis treatment will only be known after 
additional, multiyear phase 3 trials.
Tuberculosis diagnostics and DST: past and 
present practice
For decades, tuberculosis diagnosis in high-burden 
countries has relied almost entirely on smear microscopy, 
which is inexpensive but detects only half of all cases.10 
Additionally, smear microscopy does not provide any 
information about drug resistance, so most patients are 
put directly onto a standardised ﬁ rst-line regimen without 
any knowledge of drug susceptibility. However, the 
increasing awareness of MDR tuberculosis20 has drawn 
greater attention to the need for DST, with the initial focus 
on rifampicin DST for the diagnosis of MDR tuberculosis.
DST results are more likely to reach patients in a 
timely fashion when the DST technology allows for 
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implementation in simpler, more peripheral health-care 
settings that are closer to patients (table). The simplest 
health-care technologies might be suitable for the most 
peripheral settings (community level and health posts), 
but more complex technologies will be appropriate only 
for higher-level facilities—ie, health centres, subdistrict 
facilities, and larger district, provincial, and regional 
hospitals. The most technically demanding methods 
might be feasible only at the most centralised, national-
level facilities (one or more of which typically operate as 
a reference laboratory for quality assurance).
New DST assays have been moving down this 
continuum; early assays were suitable only for 
centralised sites, but newer technologies are able to be 
used at more intermediate or peripheral sites. 
Development and ﬁ eld testing have led WHO to 
recommend automated liquid culture systems (in 2007), 
line-probe assays (in 2008), and the Xpert MTB/RIF test 
(in 2010). These systems oﬀ er beneﬁ ts such as reduced 
time to detection of resistance (from eﬀ ectively 106 days 
with conventional DST to 20 days with line-probe assay 
and less than 1 day with the Xpert MTB/RIF assay),21 
thus allowing for more rapid initiation of MDR 
tuberculosis treatment.22–24 Liquid culture and line-probe 
assays can be implemented in national and regional 
reference laboratories, and the Xpert MTB/RIF assay 
(an automated, cartridge-based, real-time PCR assay) in 
more peripheral sites such as subdistrict laboratories. 
Before more recent developments, the primary 
method for tuberculosis DST involved the culturing of 
M tuberculosis; these phenotypic growth assays are slow 
and need sophisticated facilities with high bio-
containment. For some MDR tuberculosis drugs, even 
phenotypic DST is not well established, and will need to 
be further researched because data are insuﬃ  cient to 
calculate clinically relevant threshold concentrations.25 
Other phenotypic (growth-based) diagnostics, such as 
the microscopic observation drug-susceptibility assay 
and the nitrate reductase assay, might be an interim 
solution for resource-limited settings.26 However, due to 
the very slow growth of M tuberculosis in phenotypic 
assays, truly rapid testing needs a molecular approach 
that avoids the need to grow M tuberculosis and instead 
uses molecular biology methods to detect resistance-
associated mutations in DNA. Such molecular assays 
are the primary focus of this Series paper.
Line-probe assays, though molecular, also present 
challenges. As with liquid culture, they need laboratory 
infrastructure that is not available at the periphery of the 
health-care system (eg, at health centres, district hospitals, 
or even most provincial hospitals), so they are not 
practical for routine testing of all individuals with 
conﬁ rmed or suspected tuberculosis in most high-burden 
countries.27 Such a step would need a massive sputum 
sample referral and transport system that typically does 
not exist. Instead, cultures and line-probe assays are used 
largely for patients at high risk of resistance—eg, those 
with persistent symptoms. 
The Xpert MTB/RIF test, however, has great potential 
because it can be used at the district or subdistrict level.28 
It not only detects rifampicin resistance, but also detects 
far more tuberculosis cases than does smear microscopy, 
particularly in regions where many people are co-infected 
with HIV and tuberculosis.21 As a result, the Xpert MTB/
RIF assay has been scaled up rapidly in South Africa, 
where it is used as the ﬁ rst diagnostic for all individuals 
DST in centralised laboratories (status quo for most 
high-burden countries)
DST in peripheral settings (eg, microscopy centres or district 
laboratories)
Technology requirements Advantage: centralised laboratories allow for deployment 
of high-throughput, sophisticated assays (eg, microarrays, 
DNA sequencing, beacons, real-time PCR); these methods 
might be better suited to assaying many mutations and 
more drugs
Disadvantage: this setting might constrain technology to simpler 
platforms, which might not be ideal for new drugs or the addition 
of more drugs or mutations; the accompanying sample preparation 
technique should not need a laboratory with high levels of 
biocontainment
Cost Advantage: centralised DST can be used only for 
subpopulations of patients, reducing volume and costs; 
samples can be batched to further increase cost eﬃ  ciency
Disadvantage: DST assays for peripheral settings might be more 
expensive and not cost eﬃ  cient (lower test volume); the overall 
cost of tuberculosis diagnosis might increase and health systems 
could be unwilling to make such big investments, unless MDR 
tuberculosis prevalence is very high
Quality Advantage: quality testing and reliable results are easier to 
ensure in a small number of centralised laboratories 
Disadvantage: unless very simple or automated, DST in the 
periphery will need extensive quality assurance, training, and 
personnel
Timeliness and use of 
results
Disadvantage: turnaround times are too long and losses to 
follow-up are high, both with samples sent and patients 
who never come back for results; DST results are often not 
reviewed when they become available, and many results 
never get reported or used
Advantage: if universal DST is needed at the time of tuberculosis 
diagnosis, then it has to be done in peripheral settings where most 
tuberculosis cases are diagnosed; rapid turnaround and lower losses 
to follow-up will mean doctors can actually act on the DST results 
and modify treatment decisions; they are likely to pick up MDR 
tuberculosis much earlier, before substantial transmission occurs
Sample transport and 
reporting system
Disadvantage: needs good sample transport and a 
reporting system, which is not available in many settings
Advantage: does not need an extensive sample transport and 
reporting system
DST=drug susceptibility testing. MDR=multidrug-resistant. 
Table: Advantages and disadvantages of centralised and peripheral DST
For more on the Xpert MTB/RIF 
assay see Series Lancet Infect Dis 
2013; published online March 24. 
http://dx.doi.org/10.1016/
S1473-3099(13)70008-2/
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with suspected tuberculosis. In other countries, such as 
Kenya, it is used for all HIV-infected individuals with 
suspected tuberculosis. Other resource-limited countries, 
however, still struggle with the cost,29 electricity, and 
maintenance requirements of this assay.30 Although the 
price of the Xpert technology has been reduced to under 
US$10 per cartridge, this negotiated price is not available 
to the large number5 of patients with tuberculosis in the 
private health sector in some high-burden countries.31 
The roll-out of the Xpert MTB/RIF assay has been 
associated with diﬃ  culties that will probably also be 
applicable to DST development for new tuberculosis 
regimens. One major issue is positive predictive value.32,33 
Even with a pooled sensitivity for rifampicin resistance of 
94% and a pooled speciﬁ city of 98%,34 the latest iteration 
of the Xpert MTB/RIF assay has a positive predictive 
value for MDR tuberculosis of only about 50% or 67% 
when rifampicin resistance prevalence is 1% or 2%, 
respectively.32 Such resistance values are typical in new 
patients with tuberculosis, and the low positive predictive 
value results in many false positives and a substantial 
demand for conﬁ rmatory DST.35 (Of note, however, even 
smear culture is not 100% accurate, so the true speciﬁ city 
of the Xpert assay for rifampicin resistance might be 
higher than the initially reported 98%.) In many 
countries with low HIV or MDR tuberculosis prevalence, 
the issues of positive predictive value and costs have 
restricted the uptake of the Xpert MTB/RIF assay. 
Future needs: alignment of new drug regimens 
and new diagnostics
Selecting drugs to test and ways to test them 
Which of the new drugs are the most important targets 
for future DST? Typically, DST has focused on drugs for 
which resistance has one or more of three consequences: 
it undermines treatment eﬀ ectiveness, it increases the 
risk of resistance ampliﬁ cation, or it strongly predicts 
resistance to other drugs (ie, acts as a triage assay). At 
present, rifampicin DST has been prioritised to 
diagnose MDR tuberculosis.36 Evidence suggests 
isoniazid DST should also be done: substantial numbers 
of patients harbour isoniazid-resistant, rifampicin-
susceptible strains, and patients with such strains have 
reduced treatment success.37,38 For implementation of 
the 4 month regimens, DST to detect susceptibility to 
rifampicin and ﬂ uoroquinolones will be of interest, 
especially in countries that already do DST for 
rifampicin. For the PaMZ regimen, a rapid test for 
moxiﬂ oxacin and pyrazinamide would probably be the 
ﬁ rst priority, because clinically signiﬁ cant resistance to 
PA-824 has not yet been shown. Development of DST 
for PA-824 and other new drugs will be prioritised—
initially for use in surveillance—as resistance to them 
develops and their use becomes more widespread.
After deciding which drugs to test, additional 
information is needed. To be rapid and clinically useful, a 
DST assay will probably need to be molecular. Therefore, 
information about resistance mutations—and the cor-
relation of those mutations with clinical outcomes—is 
needed to form the basis for such a test.
The Xpert MTB/RIF assay’s 94% sensitivity for 
detection of rifampicin resistance is only possible 
because almost every mutation contributing to 
rifampicin resistance is known and present in a short, 
deﬁ ned DNA region. For ﬂ uoroquinolones, however, 
incomplete knowledge of all contributing resistance 
mutations outside the quinolone-resistance determining 
regions of gyrA and gyrB means that sensitivity with 
such molecular methods would, on the basis of current 
knowledge, be limited to about 85%.26,39 As occurred 
recently for a line-probe assay for second-line drugs, 
when an assay has insuﬃ  cient sensitivity, it might be 
recommended for use as a rule-in test only.10,35 Sensitivity 
might be enhanced by incorporation of additional, low-
abundance mutations, but doing so might reduce 
speciﬁ city to an unacceptable level—eg, if speciﬁ city for 
each of ﬁ ve independent mutations is 98%, the overall 
speciﬁ city of a test including all ﬁ ve mutations would be 
0·985 or 90%. Other major issues, for ﬂ uoroquinolones 
and other drugs, are the possibility of multigenic 
resistance and the diﬃ  culty of detecting already-known 
mutations from a mixed population of bacilli.40 
DST for pyrazinamide poses even more challenges. 
The activation of pyrazinamide requires pH levels that 
are diﬃ  cult to maintain in culture media, so phenotypic 
DST for pyrazinamide is inconsistent. Analysis of the 
sequence of one resistance gene (pncA) has been 
proposed as an alternative, although this approach 
might detect only about 90% of pyrazinamide 
resistance.41 The mutations are spread along the entire 
length of the pncA gene, however, necessitating analysis 
of a fragment of roughly 700 bp. This drawback has led 
to the idea of testing for the presence of a wild-type gene 
(rather than testing for the presence of a speciﬁ c 
mutation) as a way of ruling out resistance. In this 
approach, silent mutations, which do not confer 
resistance, would probably prevent hybridisation and 
thus yield false positives. These silent mutations, 
although rare,42 need to be better characterised by 
standardised and validated culture-based pyrazinamide 
resistance assays and incorporated into a molecular 
testing algorithm.
To minimise these limitations, one priority in 
translational science is to link gene mutations to 
phenotypic resistance (ie, the amount of drug needed to 
inhibit bacterial growth).43,44 A second priority is to 
develop strain collections (preferably sequenced45,46) that 
will assist with the testing of new diagnostic assays and 
the development of genomic databases that would predict 
drug susceptibility phenotypes. For new drugs, isolates 
that develop resistance in vitro should be stored for later 
assessment, but their clinical signiﬁ cance will be unclear 
until resistance is noted in clinical use. Compound 
availability for such clinical assessment and data for 
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crucial breakpoints are likely to emerge only after 
regulatory approval of new tuberculosis drugs. Post-
marketing studies will be important to identify treatment 
failures and resistance mechanisms.
Surveillance: a basis for decision making
Once translational science has provided a means to 
detect resistance, the next task will be to establish 
existing or emerging resistance levels via surveillance. 
Data for global drug resistance obtained through WHO’s 
Global Project on Anti-TB Drug Resistance Surveillance 
is available from 135 of 194 member states, of which only 
63 countries have continuous surveillance systems that 
use DST.10 Generally, surveillance is restricted to 
activities that align with current rather than future 
treatment priorities. Most countries assess resistance to 
isoniazid, rifampicin, and ethambutol (pyrazinamide is 
often excluded, because of the methodological challenges 
already discussed) in new and retreated patients. 
Resistance to ﬂ uoroquinolones is assessed only in 
patients with MDR tuberculosis because these patients 
are the only ones recommended to take ﬂ uoroquinolones 
by WHO and the International Union Against 
Tuberculosis and Lung Diseases; however, a substantial 
amount of ﬂ uoroquinolone use is believed to occur in 
ﬁ rst-line tuberculosis treatment in the private sector of 
some countries.5
Such data are insuﬃ  cient to assess development and 
implementation priorities for new tuberculosis regimens 
and diagnostics. The key information gap for the 
REMoxTB regimens is ﬂ uoroquinolone resistance in 
new patients. Although existing data suggest that such 
resistance is very low in most47–49 but not all50,51 countries, 
the absence of such data for most high-burden countries 
makes it diﬃ  cult for a country to assess the cost-
eﬀ ectiveness of the new regimen (ie, one factor in 
deciding whether to implement) or the most appropriate 
DST algorithm (ie, how to implement). And, for PaMZ, 
pyrazinamide resistance rates in both new and MDR 
tuberculosis patients are missing. For both moxiﬂ oxacin 
and pyrazinamide resistance, some data are available 
from clinical trials, but nationally representative data are 
sorely needed. As new drugs with new mechanisms of 
action are adopted, surveillance will also be needed to 
monitor for the development of resistance to bedaquiline, 
delamanid, and others.
For surveillance data to be meaningful, the data should 
be representative of either a national or subnational 
population, be obtained using quality-assured assays, and 
distinguish between resistance rates in new patients and 
retreated patients. Ideally, DST surveys should be linked 
with treatment outcomes and patient care (although 
methods with high quality assurance would be needed) 
and would make use of new, high-throughput molecular 
methods that would be much faster than current growth-
based assays. For example, with a suﬃ  cient foundation of 
mutation data,43 sequence-based assays can provide rapid 
and accurate information and, for many drugs, good 
correlation with DST obtained with liquid culture.46 
DNA sequencing—as a centralised procedure—is 
more practical for surveillance than for patient care. But 
even for surveillance, it is important to develop fast and 
safe specimen preparation, transport methods that 
maintain stability of the DNA in the specimen, and 
templates, primers, barcodes, and standardised electronic 
reporting. Such systems should improve in accuracy as 
mutations with unknown association are obtained and 
analysed; however, while this knowledge is being 
accumulated, parallel implementation of phenotypic and 
molecular assays might be needed.
Collaboration with a country undertaking a drug 
resistance survey could provide an opportunity to pilot 
the technology and develop the systems described above. 
Such a study could provide the proof of principle and the 
data to validate such a system. 
Modelling of alternative DST strategies
Drugs and diagnostics are implemented as individual 
elements of a larger, more complex tuberculosis 
management system. In the public health approach, all 
incoming patients are subdivided into just a few 
treatment pathways. Central to this management 
system are diagnostic algorithms, which consist of 
diﬀ erent permutations of drugs to test for, the level of 
the health-care system at which the testing is done, the 
selection of the patient population eligible for testing, 
and decisions about single-step or multiple-step testing. 
At the end is a treatment decision. New regimens 
introduce several new variables to consider when 
deciding which algorithms are most eﬀ ective, and data 
to inform this decision will be scarce at the time any 
new regimen is introduced. Mathematical models can 
be useful to guide decision making in such instances in 
which direct data are scarce.52 
Such models use existing data to simulate simpliﬁ ed 
tuberculosis epidemics that behave according to best 
current knowledge. These models can then be used to 
project the medium-term incidence and prevalence of 
drug-resistant tuberculosis at the population level under 
various assumptions about the deployment of new 
regimens and corresponding DST.
For example, one priority question is where DST should 
be placed in treatment algorithms for various 
epidemiological and economic contexts. Clearly, the ideal 
algorithm (from a perspective of reducing drug resistance) 
is to deploy DST for all people with conﬁ rmed or suspected 
tuberculosis, with conﬁ rmatory testing of preliminary 
positives. Preliminary modelling has suggested that the 
so-called test-early strategy for isoniazid and rifampicin 
might be cost eﬀ ective in areas with an underlying MDR 
tuberculosis prevalence as low as 2·1%.53 However, this 
strategy is only feasible in areas where good DST exists for 
a given regimen, resources are suﬃ  cient to deploy such 
DST widely, and use of DST will not greatly delay initiation 
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of treatment. Most high-burden settings therefore cannot 
consider such algorithms at this time. 
A history of previous treatment is a strong 
independent risk factor for resistance, so DST should 
be directed at these subpopulations. But when should 
DST be implemented more broadly? For large public 
health programmes in resource-limited high-burden 
countries, it might make sense to implement DST only 
when the prevalence of resistance to a given drug rises 
above a speciﬁ c threshold. Below this level, the 
implementation challenges and issue of false positives 
outweigh the risks from undetected resistance. Above 
this level, action is needed to prevent worsening 
treatment outcomes, resistance ampliﬁ cation, and 
increased transmission. But generally the point at 
which this threshold should be set in diﬀ erent 
epidemiological and economic conditions is unclear—
especially when MDR tuberculosis hot spots occur 
within countries that otherwise have low overall 
prevalence.54 The answer will also vary depending on 
whether the remaining drugs in the regimen will still 
protect the person from resistance generation and 
disease progression. Modelling could help to assess 
which thresholds make sense in terms of public health 
beneﬁ t, cost, and cost-eﬀ ectiveness. 
Two questions have arisen in discussions of modelling 
DST in the context of new tuberculosis regimens. First, 
what would diﬀ erent DST assays—with diﬀ erent speed, 
accuracy, price, and technical speciﬁ cations (ie, which 
drugs, how many mutations)—achieve in terms of a 
population-level eﬀ ect and cost-eﬀ ectiveness, and what 
are the trade-oﬀ s between these various speciﬁ cations? 
Second, what is the population-level eﬀ ect and cost-
eﬀ ectiveness of diﬀ erent DST algorithms (eg, DST for 
all, DST for only patients who are being re-treated or in 
whom previous treatment had failed, or use of new 
regimens without DST) as a function of baseline drug 
resistance and rate of emerging resistance?
Those deciding how to deploy DST should consider 
the projected epidemiological outcomes, budgetary 
constraints, feasibility concerns, and political realities. 
Mathematical models can assist with the ﬁ rst of these 
(projections of potential outcomes), and thereby serve 
as an important tool for decision makers. However, 
these models are restricted by the quality of data; in 
particular, data are sparse for the extent of drug 
resistance in many high-burden areas and the rate at 
which resistance to second-line drugs (eg, 
ﬂ uoroquinolones) might emerge under pressure from 
new regimens. Thus, even when restricted to the 
outcomes issue, mathematical models cannot validate 
which assumptions about emergence of drug resistance 
are correct. However, they can project epidemiological 
outcomes under best-guess assumptions of these data-
points, describe the range of uncertainty, emphasise the 
data for which surveillance is most crucial as new 
regimens are deployed, and provide preliminary 
guidance in line with current knowledge while those 
data are obtained.
Development of new DST assays
Information about resistance rates (from surveillance) 
and algorithm choice (from modelling) can directly 
inform the ﬁ nal question: what new DST assays need to 
be developed? A target product proﬁ le (TPP) is a list of 
product speciﬁ cations, including projected product 
performance and target patient population. The TPP of a 
DST assay will vary depending on the intended use 
(individual treatment decisions vs surveillance), the 
epidemiology (detecting low vs high resistance), the 
health-system context (where it is positioned in possible 
algorithms), and whether the technology will be used in 
central or peripheral settings. 
Example TPPs and DST approaches have been described 
elsewhere.55,56 Beyond the target drug(s), these TPPs should 
address several issues: what is meant by rapid; what level 
of sensitivity and speciﬁ city a DST assay needs for it to be 
practical and feasible; what other diseases should be able 
to use the same DST platform technology; and what level 
of complexity, containment, and cost are needed. 
But two related issues stand out. First, should DST be 
bundled into case-detection assays (as with the Xpert 
MTB/RIF assay), or should it be a reﬂ ex test that is done 
only after tuberculosis is diagnosed? Of the two 
approaches, reﬂ ex testing needs more patient samples 
(and potentially more patient visits, with associated loss 
to follow-up and delays in treatment initiation). But reﬂ ex 
testing means that only patients with conﬁ rmed, rather 
than suspected, tuberculosis undergo DST, which can 
greatly reduce costs. 
Second, new DST assays could be developed for 
deployment at either centralised laboratories or the more 
Panel 1: Diagnostics developers’ requirements beyond 
target product proﬁ les63
Potential market size
• Size of the target population
• Market reach of competing drug susceptibility testing 
technologies
• Diagnostic algorithms used now and in the future; current 
and future tuberculosis treatment landscape
• Segmentation of markets by income and by peripheral 
versus centralised methods
• Projected scale-up dynamics
Practical steps 
• Sources of funding and technical support, especially for 
validation trials
• Whether validation trials can address only accuracy or also 
have to show clinical eﬀ ect
• Requirements for regulatory and policy approvals
• Potential procurement and scale-up challenges at the 
country level
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peripheral levels of the health-care system (table). Emerging 
technologies for DST are abundant—including micro-
arrays, next-generation sequencing, line-probe assays, 
molecular beacons, high-resolution melt curve analysis, 
lights on/lights oﬀ  technology, cyclic catcher melt 
temperature analysis, phenotypic colour tests, pyrazin-
amidase assays, and combination phage and molecular 
assays—and some of these technologies can be readily 
adapted to increase the number of mutations detected, but 
few are suited to use in peripheral laboratories. 
Therefore, investment will be needed either to develop 
cost-eﬀ ective and robust DST methods for peripheral 
laboratories, or to create rapid, reliable sample transport 
systems to support centralised DST (along with mobile-
health and patient-incentive solutions to reduce delays 
and dropouts). Deployment of testing at the point of 
treatment can bring obvious advantages, such as reduced 
delay and dropout, but can add substantially to the overall 
cost because of the many instruments needed and the 
lower volumes of testing per site.57 
Many countries diagnose drug-sensitive tuberculosis at 
the peripheral levels of the health system, but initiate 
treatment at the subdistrict level. Therefore, a 
compromise might be to have a new, sensitive case-
detection assay as a true point-of-care assay, followed by 
DST given as a reﬂ ex assay at subdistrict level at the time 
of treatment initiation.
If non-centralised DST remains the strategy, simplicity 
should be a major goal.58 Simpliﬁ ed smear microscopy 
algorithms provide an interesting example of how up-
front performance (in this case, sensitivity) is sometimes 
worth sacriﬁ cing in return for a protocol that is simpler 
for the patient (with lower travel costs) and that therefore 
is associated with less dropout and better overall 
eﬀ ectiveness.59,60 Modelling studies61,62 have already 
resulted in similar conclusions for new diagnostics. 
Improved assay sensitivity provides some epidemiological 
gains, but the greater population eﬀ ect comes from a 
focus on test speciﬁ cations that allow peripheral use and 
fast turnaround times, thus reducing patient delays and 
default.61,62 
One option for a peripheral laboratory test is to focus 
on excluding all patients who are likely to be resistant; 
high sensitivity becomes the goal and speciﬁ city 
becomes less important. A test with lower speciﬁ city can 
be acceptable if the prevalence of resistance is high, if an 
eﬀ ective and safe alternative regimen (eg, 2HRZE/4RH 
for PaMZ) is available, or if used as a triage test. One 
example of an approach that prioritises sensitivity is the 
proposed molecular assay to screen for the wild-type 
pncA gene as a correlate for pyrazinamide susceptibility, 
rather than trying to capture the many diﬀ erent pncA 
mutations that can lead to pyrazinamide resistance. 
Another option is to continue—even with new 
regimens—to focus on rifampicin resistance screening 
as a ﬁ rst step. Preliminary evidence17 suggests that 
rifampicin-resistant strains are more likely than 
rifampicin-sensitive strains to be resistant to 
pyrazinamide and ﬂ uoroquinolones. Therefore, DST for 
rifampicin might be a useful triage test even if the ﬁ rst-
line regimen does not contain rifampicin (eg, PaMZ). 
The subsequent pyrazinamide and ﬂ uoroquinolone DST 
could then be restricted to a smaller population with a 
higher prevalence of resistance.
All of this theory is irrelevant unless companies invest 
in the development and testing of new tuberculosis 
diagnostics. These developers should be aware of what is 
needed in resource-limited settings and be willing to take 
a product all the way through ﬁ eld testing to 
Panel 2: Framework to achieve successful implementation of new tuberculosis 
regimens and drug susceptibility testing (DST)
Short term
• Identify all mutations in Mycobacterium tuberculosis that occur reasonably frequently 
and that result in resistance to existing and new drugs; priority should be placed on 
obtaining resistance information from clinical samples that are accompanied by 
treatment outcome data
• Develop a collection of sequenced sensitive and resistant strains that can be used to 
assess new DST assays
• Use modelling to deﬁ ne which strategies for deployment of DST will have the greatest 
population-level eﬀ ect and be most cost eﬀ ective; various strategies would include 
diﬀ erent DST assays that vary in their speed, sensitivity and speciﬁ city, cost, and 
technical speciﬁ cations and diﬀ erent DST algorithms, used in the context of various 
baseline resistance levels
• Undertake surveillance of moxiﬂ oxacin resistance in new patients with tuberculosis 
and of pyrazinamide resistance in new and previously treated patients, and patients 
with and without multidrug-resistant tuberculosis
• Do operational research to assess and optimise systems for sputum transport and 
reporting results (including prompt initiation of treatment in response)
• Develop clear target product proﬁ les to guide diagnostics developers about the 
necessary product speciﬁ cations and likely market demand
• Do analyses of the tuberculosis diagnostics market size and potential to inform 
investment decisions by test developers
Medium term
• Use existing diagnostics platforms to develop, ﬁ eld test, and commercialise DST 
assays—particularly for ﬂ uoroquinolones and pyrazinamide—that can be 
implemented at the subdistrict level
• Monitor for clinical resistance generated during the roll-out of new tuberculosis drugs 
(ie, new chemical entities) and identify the molecular basis for such resistance 
• Reﬁ ne models of long-term impact based on early surveillance data during roll-out of 
novel regimens
• Develop DST assays for new tuberculosis drugs and use them to do ongoing 
surveillance
• Develop and strengthen systems for using next-generation sequencing for 
tuberculosis drug surveillance
Long term
• Develop new diagnostic platforms that are rapid, inexpensive, and can be 
implemented at the subdistrict level
• Develop a universal regimen for tuberculosis that has at least three novel chemical 
entities and that therefore minimises the need for DST while treating all forms of 
tuberculosis
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commercialisation. The perception that these assays 
have little commercial opportunity is a substantial barrier 
to development, and supportive ﬁ nancing will probably 
still be needed. In addition to the TPP issues listed 
previously, diagnostics developers are interested in 
potential market size and the practical steps needed for 
test development, validation, regulation, and policy 
(panel 1).63 
Developers targeting surveillance have a particularly 
small market, although the barrier to entry is much 
lower because these high-throughput, centralised 
machines can be built on the presumption that users 
will have a high level of skill and that the machine will 
have applications beyond tuberculosis. For developers 
interested in peripheral DST for patient care, the 
demands in terms of assay simpliﬁ cation and robustness 
increase greatly, and market size is very dependent on 
the resistance thresholds for testing. Test developers 
might therefore be more interested in a product that 
combines tuberculosis detection and DST because this 
product will have a larger market than a DST-only 
product.
Private sector procurement is a major strategic gap. If 
new DST assays are highly priced, few private 
practitioners will use them, and DST will be missing 
from the sector that is most likely to adopt new drugs 
quickly and in the context of variable regimens. To solve 
this issue, a mechanism is needed to ensure that private 
laboratories pass along any savings from assays 
purchased at concessionary prices.
Although demonstration projects for diagnostics need 
substantial investment, assay development with existing 
platforms can be cheap by comparison. But even to 
make these investments, diagnostic companies need a 
prediction of user needs (where the user is often a 
national tuberculosis programme) and market demand. 
Deﬁ ning a clear set of speciﬁ cations for the desired 
DST—and the likely demand for such DST—is the next 
major point of collaboration for drug and diagnostic 
developers.
Conclusion 
The prospect of new tuberculosis regimens is exciting, 
because patients have had to rely on a single lengthy 
treatment option for decades. Several opportunities are 
available to mitigate the risks of developing resistance 
to these new regimens. Assays to detect resistance can 
be developed before repurposed drugs come to market 
and early in the implementation of new drugs. 
Surveillance DST can identify areas where some 
regimens might be compromised by high levels of 
background resistance, and treatment decisions can, in 
some settings, be tailored to the individual by rapid DST 
before treatment. Modelling studies will help to assess 
costs, outcomes, and feasibility to predict im-
plementation approaches. Panel 2 outlines a framework 
to achieve these goals. W hen all of these strategies are 
brought to bear, drugs and diagnostics will together 
make a powerful combination.
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